Sarcopenia As a Risk Factor of Progression-free Survival in Patients with Metastases: a Systematic Review and Meta-analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2023 Feb 8

PMID 36750774

Authors

Lingli Luo

Xiangru Shen

Shuai Fang

Teng Wan

Pan Liu

Peiling Li

Haifeng Tan

Yong Fu

Weiming Guo

Xiaojun Tang

Affiliations

Soon will be listed here.

Abstract

Background: Metastasis of cancer causes more than 90% of cancer deaths and is severely damaging to human health. In recent years, several studies have linked sarcopenia to shorter survival in patients with metastatic cancer. Several predictive models exist to predict mortality in patients with metastatic cancer, but have reported limited accuracy.

Methods: We systematically searched Medline, EMBASE, and the Cochrane Library for articles published on or before October 14, 2022. Pooled Hazard Ratio (HR) estimates with 95% confidence intervals (CIs) were calculated using a random effects model. The primary outcome was an increased risk of death or tumor progression in patients with metastatic cancer, which is expressed as progression-free survival (PFS). In addition, we performed subgroup analyses and leave-one-out sensitivity analyses to explore the main sources of heterogeneity and the stability of the results.

Results: Sixteen retrospective cohort studies with 1,675 patients were included in the 888 papers screened. The results showed that sarcopenia was associated with lower progression-free survival (HR = 1.56, 95% CI = 1.19-2.03, I2 = 76.3%, P < 0.001). This result was further confirmed by trim-and-fill procedures and leave-one-out sensitivity analysis.

Conclusions: This study suggests that sarcopenia may be a risk factor for reduced progression-free survival in patients with metastatic cancer. Further studies are still needed to explain the reason for this high heterogeneity in outcome.

Trial Registration: CRD42022325910.

Citing Articles

Sarcopenia in Terminally Ill Patients with Cancer: Clinical Implications, Diagnostic Challenges, and Management Strategies.

Go S, Kang M, Kim H J Hosp Palliat Care. 2025; 28(1):10-17.

PMID: 40070849 PMC: 11891026. DOI: 10.14475/jhpc.2025.28.1.10.

The impact of reduced skeletal muscle mass at stroke onset on 3-month functional outcomes in acute ischemic stroke patients.

Kim K, Jung S, Cho E, Yang T, Kim S, Kim H PLoS One. 2025; 20(1):e0313368.

PMID: 39813183 PMC: 11734988. DOI: 10.1371/journal.pone.0313368.

Sarcopenia as a Prognostic Factor and Multimodal Interventions in Breast Cancer.

Du L, Liu X, Zhu Q, Zhu K, Li P Int J Gen Med. 2025; 17:6605-6616.

PMID: 39764482 PMC: 11701243. DOI: 10.2147/IJGM.S497897.

Sarcopenia.

Sayer A, Cooper R, Arai H, Cawthon P, Essomba M, Fielding R Nat Rev Dis Primers. 2024; 10(1):68.

PMID: 39300120 DOI: 10.1038/s41572-024-00550-w.

Dietary Protein and Physical Exercise for the Treatment of Sarcopenia.

Nasso R, dErrico A, Motti M, Masullo M, Arcone R Clin Pract. 2024; 14(4):1451-1467.

PMID: 39194921 PMC: 11352344. DOI: 10.3390/clinpract14040117.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Ludmir E, McCaw Z, Fuller C, Wei L . Progression-free survival in the ICON8 trial. Lancet. 2020; 396(10253):756. DOI: 10.1016/S0140-6736(20)31175-2. View

Curcio F, Testa G, Liguori I, Papillo M, Flocco V, Panicara V . Sarcopenia and Heart Failure. Nutrients. 2020; 12(1). PMC: 7019352. DOI: 10.3390/nu12010211. View

Hua X, Liao J, Huang X, Huang H, Wen W, Long Z . Sarcopenia is associated with higher toxicity and poor prognosis of nasopharyngeal carcinoma. Ther Adv Med Oncol. 2020; 12:1758835920947612. PMC: 7444117. DOI: 10.1177/1758835920947612. View

Waalboer R, Meyer Y, Galjart B, Olthof P, van Vugt J, Grunhagen D . Sarcopenia and long-term survival outcomes after local therapy for colorectal liver metastasis: a meta-analysis. HPB (Oxford). 2021; 24(1):9-16. DOI: 10.1016/j.hpb.2021.08.947. View

Aleixo G, Williams G, Nyrop K, Muss H, Shachar S . Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review. Breast Cancer Res Treat. 2019; 177(3):569-579. DOI: 10.1007/s10549-019-05352-3. View

da Cunha L, Silveira M, Mendes M, Costa F, Macedo L, de Siqueira N . Sarcopenia as an independent prognostic factor in patients with metastatic colorectal cancer: A retrospective evaluation. Clin Nutr ESPEN. 2019; 32:107-112. DOI: 10.1016/j.clnesp.2019.04.004. View

Trejo-Avila M, Bozada-Gutierrez K, Valenzuela-Salazar C, Herrera-Esquivel J, Moreno-Portillo M . Sarcopenia predicts worse postoperative outcomes and decreased survival rates in patients with colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2021; 36(6):1077-1096. DOI: 10.1007/s00384-021-03839-4. View

Blauwhoff-Buskermolen S, Versteeg K, de van der Schueren M, den Braver N, Berkhof J, Langius J . Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2016; 34(12):1339-44. DOI: 10.1200/JCO.2015.63.6043. View

10.

Fearon K, Strasser F, Anker S, Bosaeus I, Bruera E, Fainsinger R . Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12(5):489-95. DOI: 10.1016/S1470-2045(10)70218-7. View

11.

Bischoff-Ferrari H, Orav J, Kanis J, Rizzoli R, Schlogl M, Staehelin H . Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. Osteoporos Int. 2015; 26(12):2793-802. DOI: 10.1007/s00198-015-3194-y. View

12.

Grossberg A, Chamchod S, Fuller C, Mohamed A, Heukelom J, Eichelberger H . Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2016; 2(6):782-9. PMC: 5080910. DOI: 10.1001/jamaoncol.2015.6339. View

13.

Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C . Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res. 2009; 15(20):6391-7. PMC: 2779768. DOI: 10.1158/1078-0432.CCR-09-0877. View

14.

Skipworth R, Stewart G, Dejong C, Preston T, Fearon K . Pathophysiology of cancer cachexia: much more than host-tumour interaction?. Clin Nutr. 2007; 26(6):667-76. DOI: 10.1016/j.clnu.2007.03.011. View

15.

Bone A, Hepgul N, Kon S, Maddocks M . Sarcopenia and frailty in chronic respiratory disease. Chron Respir Dis. 2016; 14(1):85-99. PMC: 5720213. DOI: 10.1177/1479972316679664. View

16.

Haik L, Gonthier A, Quivy A, Gross-Goupil M, Veillon R, Frison E . The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. Acta Oncol. 2021; 60(12):1597-1603. DOI: 10.1080/0284186X.2021.1978540. View

17.

von Haehling S . The wasting continuum in heart failure: from sarcopenia to cachexia. Proc Nutr Soc. 2015; 74(4):367-77. DOI: 10.1017/S0029665115002438. View

18.

van Vugt J, Braam H, van Oudheusden T, Vestering A, Bollen T, Wiezer M . Erratum to: Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer. Ann Surg Oncol. 2015; 22 Suppl 3:S1610. DOI: 10.1245/s10434-015-4467-6. View

19.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

20.

Ryall J, Schertzer J, Lynch G . Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. Biogerontology. 2008; 9(4):213-28. DOI: 10.1007/s10522-008-9131-0. View